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Abstract This study evaluates the clinical effectiveness
of targeted arterial infusion of verapamil in interventional
treatment of primary hepatocellular carcinoma. For this
purpose, in 273 patients with middle- or late-stage primary
hepatocellular carcinoma, verapamil, IL-2, and chemo-
therapeutic agents were infused into the target tumor vas-
culature through femoral artery using Seldinger technique.
The medications were infused as serial dilutions, and
effectiveness was evaluated after two treatment cycles.
Among these 273 patients, 76 cases showed clinical cure or
signiﬁcant improvement, 119 cases improved, 64 cases
stabilized, while 14 cases progressed or deteriorated. In
238 patients, KPS score and body weights were stabilized.
Regarding side effects, 99 patients (36.3%) developed
leukopenia; 160 patients had gastrointestinal reactions
(58.6%); 80 patients (29.3%) presented with elevated ALT/
AST proﬁle; and 65 cases (23.8%) had pyrexia; however,
these side effects abated quickly. No elevations in BUN/Cr
and/or allergic reactions were observed. Pre- and post-
intervention cardiac function did not change in all the
patients. No signiﬁcant change was observed in ECG. Liver
function was also improved after two cycles of treatment.
It was concluded that verapamil management via targeted
arterial infusion could effectively reverse the multidrug
resistance in cancer cells in primary hepatocellular carci-
noma patients and therefore enhanced the efﬁcacy of
chemotherapy.
Keywords Verapamil  Arterial perfusion  Primary
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P-glycoprotein
Introduction
Primary liver cancer is one of the common malignant
tumors, is ranked 6th in cancer incidence rates, and 3rd by
death in the world [1]. Presently, surgical excision is the
main treatment method with regard to patients with pri-
mary liver cancer but about 15% of patients can be bene-
ﬁted from it in the long run [2]. Given the fact that the
onset of liver cancer is more hidden with no obvious
symptoms, most patients are diagnosed at the middle or
later stages and thus lose the opportunity of a radical sur-
gical treatment. Minimally invasive treatments can have
signiﬁcant therapeutic beneﬁts in prolonging the survival
time and improving the quality of life of patients [3]. In this
regard, trans-catheter arterial chemoembolization (TACE)
is currently the preferred standard approach [4]. Since its
ﬁrst application [5], the technique has been widely used
and also further developed. However, the traditional target
arterial chemoembolization has limited treatment efﬁcacy
as 1-year cumulative survival rate was found to be 58–75%
[6–8] while the long-term survival rate was much lower,
perhaps due to development of multidrug resistance
(MDR) [9–11]. In vitro studies show that 6–10 lmoL/L
(2.94–4.91 lg/mL) verapamil completely inhibits MDR of
P-gp reversal cancer cells and increases tumor cell sensi-
tivity to chemotherapeutic drugs. However, serious car-
diovascular side effects are observed in patients with serum
concentrations of 1–2 lmoL/L (0.49–0.98 lg/mL). The
drug inhibits MDR only as the tissue concentration is 3–10
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DOI 10.1007/s12013-010-9125-9times the blood concentration [12, 13]. So far, intravenous
verapamil stage-I clinical trials have failed to achieve
satisfactory results.
First-pass effect of drugs used in hepatic arterial perfu-
sion (IA) is considered signiﬁcant in the liver uptake and
metabolism. In this concern, ﬁrst-pass hepatic uptake of
fotemustine (FM) at a dose rate of 100 mg/m
2 in patients
with liver metastases was found to be 0.9 times higher in
IA administration as compared with intravenous injection.
Thus, the amount of drug received in normal tissue was
signiﬁcantly reduced and, consequently, the side effects
were minimized [14]. Following hepatic intra-arterial
infusion of ﬂuorouracil (5-FU) at different doses and
injection speeds in pigs, the drug could not be measured in
either hepatic vein or peripheral blood and was taken up
almost entirely by the liver for metabolism [15]. In this
study, based on the previous observations in canines [16],
the authors sought to determine the chemotherapeutic
efﬁcacy and toxicity of verapamil using femoral artery




Two hundred seventy-three hospitalized patients (from
October 1999 to May 2009) of primary hepatocellular
carcinoma, comprising of 267 males and 6 females, were
enrolled in the study. AFP was tested by quantitative
chemiluminescence immunoassay (CLIA) before treat-
ment. There were 48 patients with AFP\20 lg/L, 45
patients with 20 lg/L\AFP B 200 lg/L, 59 patients with
200 lg/L\AFP B 400 lg/L, and 121patients with
AFP[400 lg/L.
Inclusion Criteria
The diagnosis of primary hepatocellular carcinoma was
made according to the clinical diagnostic criteria of
National Research Council of China [18]. The following
inclusion criteria were used for patient recruitment in the
study: Age 18–70 years; KPS score C70; Heart rate[60
beats per min; Cardiac function 0–1 level; Liver function
CHILD classiﬁcation B or above B; and Life expec-
tancy[3 months. The study was approved by the institu-
tional ethics committee of our hospital and informed
written consent was obtained from each patient before
enrolment in this treatment regimen. Only the patients in
whom Seldinger catheter could be passed through the
tumor artery were included in this study.
Exclusion Criteria
The patients were excluded from enrolment in the study
under following conditions: a history of surgical interven-
tion of the tumor, history of allergy to iodine medication,
pregnancy or breast feeding, mental illness or retardation,
acute infections, symptoms of the central nervous system,
white blood cell (WBC) count\4.0 9 10
9/L, red blood
cell (RBC) count\10.0 9 10
9/L, hemoglobin (Hb)\60
g/L or any blood coagulation disorders. Also the patients in
whom the standard treatment could not be strictly followed
for some reasons or those presenting with serious adverse
effects or the missing information cases posing difﬁculty in
proper assessment were excluded from the study.
Treatment Regimen and Hepatic Arterial Embolization
Each patient was managed with intervention therapy for
more than two cycles. One cycle was deﬁned as one time
intervention treatment per month and at least 2 cycles of
intervention treatment were given in each case. The effect
of the interventional management was evaluated after
2 months. In all patients, femoral artery was punctured
using Seldinger technique. Verapamil, IL-2, Adriamycin
(ADM), cisplatin (DDP) and 5-FU were infused into the
tumor site via celiac artery. Then the catheter was passed
into the right or left hepatic artery and embolization was
performed by using Mitomycin C(MMC) plus iodized oil.
The perfusion steps used were as follows: an emulsion was
made by dissolving verapamil (15 mg), ADM (40–50 mg/
m
2), DDP (30–50 mg/m
2), 5-FU (500–600 mg/m
2)i n
30 ml of normal saline (NS) and IL-2 (300 IU) and injected
into the branches of the hepatic artery distal to the origin of
the gastroduodenal artery. After 15 min, verapamil (10 mg)
solution in NS was re-infused. In patients with good blood
supply, MMC (10–12 mg) emulsion in 1 ml of 40% iodized
oil (Lipiodol) per cm of the maximum diameter of lesions
was injected and the vessels were embolized.
Study Parameters
The following parameters included the follow up plan:
complete blood count (CBC), liver and kidney functions,
routine urinalysis and Alpha-fetoprotein (AFP). Electro-
cardiogram (ECG), ultrasound (US) or computed tomog-
raphy (CT) was done for the 1st time before starting the
treatment intervention, for the 2nd time after 30 days, and
for the 3rd time after 60 days from the treatment. In the
meantime, information regarding medication side effects,
changes in signs and symptoms and Karnofsky perfor-
mance scale (KPS) index were also recorded. After
administering 2 cycles of intervention regimens, an
assessment of the clinical beneﬁts was performed including
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123the generation of new lesions or changes in existing
lesions, KPS index, change of body weight and AFP levels.
Heart rate and blood pressure were monitored before,
during and 5 min after the infusion of verapamil. In order
to observe the effect of verapamil administration on the
cardiovascular system during the interventional treatment,
not only monitoring of the dynamic ECG during the
operation, but also performing and comparing the pre- and
post-intervention ECG results were done. In addition,
cardiac function was evaluated for any change(s). The
patients were followed up for 1-year survival time after the
intervention. Toxicities of the anticancer drugs were eval-
uated according to the National Cancer Institution (NCI)
toxicity grade (0–4) criteria [19]. Cardiac function was
classiﬁed using the New York Heart Association (NYHA)
functional classiﬁcation (I–IV) criteria [20]. Liver func-
tions were evaluated according to Child-Pugh classiﬁcation
scores [21].
Clinical Cure or Signiﬁcant Improvement
If, after two cycles of treatment, the tumor either disap-
peared or was reduced by more than 75% and iodized, then
oil accumulation was uniform with complete occlusion of
the tumor vasculature, or residual tumor vessels were found
only in the marginal area.
Improvement
The tumor was reduced by 30–75% of its initial size with
an uneven accumulation of iodized oil such that the iodized
oil-ﬁlled area accounted for more than half of the whole
tumor mass whereas the tumor vasculature was also sig-
niﬁcantly reduced.
Stability
The reduction in tumor size was less than 30% of the initial
mass with a patchy accumulation of iodized oil such that
the iodized oil-ﬁlled area comprised less than half of the
whole tumor mass, and there was no signiﬁcant decrease in
tumor blood vessels.
Progression or Deterioration
The size of tumor mass was increased, and iodized oil was
sparsely distributed or displayed poor accumulation such
that the oil-ﬁlled area accounted for less than one-third of
the whole tumor mass. The tumor vasculature was also
found to be signiﬁcantly increased with or without for-
mation of the new arteriovenous (AV) ﬁstulas between the
hepatic artery and portal vein [22].
Treatment Efﬁcacy
The treatment efﬁcacy was evaluated based on CT scan or
US results and AFP quantitative measurements 1 month
after the second treatment cycle.
Results
Clinical Outcome
After two cycles of treatment intervention, the clinical
outcome was analyzed. Of 273 patients, 76 cases were
clinically cured, 119 cases were signiﬁcantly improved, 64
cases remained stable, and 14 cases showed disease pro-
gression or deterioration (Table 1). In 137 patients, AFP
decreased after one course of treatment, and among them,
88 cases showed a more than 50% reduction in AFP. In 35
patients, AFP dropped after receiving two treatment cour-
ses, and 20 of these individuals showed a more than 50%
AFP reduction. Of the 273 patients, 238 cases showed
Karnofsky score[20 which was maintained over a period
of 4 weeks or more, and 166 patients had a more than 7%
weight gain which was also maintained for a period of at
least 4 weeks. Two hundred ﬁfty-nine patients were fol-
lowed up for an observation period of one year, and the
1-year survival rates reached 81.8%.
Side Effects
The following side effects were recorded in the patients
after the treatment intervention. The major side effects
(Table 2) observed were as follows: 99 (36.3%): patients
developed leukopenia; 160 (58.6%) patients presented with
gastrointestinal reactions; 80 (29.3%) individuals had ele-
vated ALT/AST; and 65 (23.8%) cases had fever; however,
all these side effects quickly subsided. No allergic reactions
or elevations in BUN/Cr were observed. In all the cases, no
signiﬁcant change in the cardiac function (Table 3) was
observed before and after intervention. Also, no signiﬁcant
Table 1 Outcome of verapamil arterial infusion in primary hepatocellular carcinoma patients
Clinically cured or signiﬁcantly improved Improved Stable Progressed or deteriorated Total
No. of cases 76 119 64 14 273
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123change was found in ECG (Table 4). The liver function
(Table 5) improved after two cycles of treatment. After the
ﬁrst and second cycle of treatment, mean AST values were
87.0 and 23.0 U/L, respectively. Similarly, mean ALT
values were 98.0 and 19.0 U/L, respectively, and mean
ALP values were 289.0 and 47.0 U/L, respectively.
Following the ﬁrst and second treatment cycles, mean GGT
values were 122.0 and 37.0 U/L, respectively. All the
parameters showed signiﬁcant differences (P\0.05).
Discussion
The MDR refers to a drug-induced phenomenon in which
targeted cells become simultaneously resistant to multiple
medications with different chemical structures and mech-
anisms of action. MDR is the main culprit for the failure of
chemotherapy in the treatment of malignant tumors.
Meanwhile, MDR also constitutes one of main reasons as
to why the conventional targeted arterial embolization
intervention therapy fails in the chemotherapy of primary
hepatocellular carcinoma [11, 12].
The P-glycoprotein (P-gp) is a 170-kD glycoprotein
which is an ATPase-dependent membrane transport pro-
tein, initially found to be present in the membrane of MDR
cells, as colchicine was applied to Chinese hamster ovary
cells and a decrease in the intracellular drug concentration
was detected [23]. P-glycoprotein hydrolyzes ATP to ADP
and releases energy, binds to intracellular anti-tumor drug
in the presence of magnesium and ‘‘pumps out’’ cytotoxic
drug from cells, and hence decreases the intracellular drug
concentration, and consequently the cytotoxic effect of
anti-tumor drugs; the phenomenon is known as MDR [9–
11]. The membrane transport of P-gp plays a pivotal role in
MDR, and hence P-gp-mediated MDR is also known as the
typical MDR. The MDR genes were found to be expressed
at relatively low levels in both normal and cirrhotic liver
tissues. Since MDR gene expression is signiﬁcantly chan-
ged in untreated liver cancer, it indicates the role for an
endogenous MDR. However, in post-chemotherapy liver
cancer cells, the change in the MDR gene expression is far
more signiﬁcant and thus suggests the role for an acquired
MDR [24].
Verapamil is considered as one of the earliest known
modulators of the MDR, and it reverses the MDR by
inhibiting the P-gp synthesis—hence called as a chemo-
sensitizer. Thus, by suppressing the P-gp gene expression,
verapamil inhibits the efﬂux of anticancer drugs from
tumor cells leading to the accumulation of chemothera-
peutic agents, and hence an enhanced cytotoxicity and
efﬁcacy of chemotherapy [13]. A few in vitro studies report
that verapamil suppresses the mRNA levels of MDR genes
including transcription levels of P-gp, reverses the MDR
phenotype by also inhibiting the activity of PKC which is
required for P-gp phosphorylation, and sensitizes tumor
cells to chemotherapeutic agents by increasing the afﬁnity
Table 2 Major side effects in primary hepatocellular carcinoma
patients during intervention treatment (N = 273)
012 3 4
Leukopenia 174 35 28 31 5
Hb decreased 233 25 13 2 0
Platelet decreased 212 24 27 9 1
GI reactions 113 78 55 15 12
ALT/AST elevation 193 65 15 0 0
BUN/Cr elevation 273 0 0 0 0
Alopecia 89 135 49 0 0
Fever 208 17 22 26 0
Muscle or Joint pain 240 15 18 0 0
Allergic reaction 273 0 0 0 0
The data were analyzed using SPSS13.0 statistical software. The
means were compared using two independent samples t-test,
proportion and rate differences were determined using chi-square test.
P-value\0.05 was considered as statistically signiﬁcant
Table 3 Change in cardiac function (N = 273)
Classiﬁcation Normal I II III IV
1 Day before treatment 260 13 0 0 0
30 Days after treatment 261 12 0 0 0
60 Days after treatment 261 12 0 0 0
The cardiac function was classiﬁed according to the criteria of New
York Heart Association (NYHA). There was no signiﬁcant change in
all 273 cases before and after the treatment intervention (P[0.05)
Table 4 ECG results at 4 time points (N = 273)
Indicator P-R interval Q-T interval QRS Heart rate
0 min 0.16 ± 0.03 0.36 ± 0.03 0.08 ± 0.01 75 ± 13
5 min 0.16 ± 0.02 0.36 ± 0.03 0.08 ± 0.01 75 ± 12
10 min 0.16 ± 0.03 0.36 ± 0.03 0.08 ± 0.01 75 ± 12
20 min 0.16 ± 0.03 0.36 ± 0.02 0.08 ± 0.01 75 ± 12
50 min 0.16 ± 0.03 0.36 ± 0.03 0.08 ± 0.01 75 ± 12
Indicated time points represent the duration after verapamil infusion.
No signiﬁcant differences were found as compared with respective
means of the 0 min group (P[0.05)
Table 5 Number of cases with abnormal liver function results
(N = 273)
AST ALT GGT ALP
Pre-intervention 260 266 273 150
Post-intervention 30 35 37 21
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123between the anti-tumor agents and their corresponding
intracellular bind sites [11].
In this study, the authors found that verapamil used at a
concentration of 6–10 lmoL/L completely reversed the
MDR in malignant tumor cells by inhibiting P-gp and
enhancing sensitivity of tumor cells to chemotherapy.
However, when the serum concentration of verapamil
reaches 1–2 lmoL/L, the cardiovascular system side
effects are observed. This is the reason why use of verap-
amil is limited to clinical applications. The speciﬁcally
targeted arterial infusion of verapamil increases the tissue
drug concentration by 3–10 times the serum drug concen-
tration and hence this approach enables verapamil to
reverse MDR while body can well tolerate it [12, 13].
In this study, verapamil, IL-2, ADM, DDP, 5-FU, MMC,
and iodized oil were administered in 273 patients through
targeted arterial infusion approach. After two cycles of
treatment intervention, 76 cases were cured or signiﬁcantly
improved, 119 cases improved, 64 cases stabilized, and 14
cases progressed or deteriorated. In 137 cases, AFP
decreased after 1 cycle of treatment while in 35 cases AFP
decreased after two treatment cycles. In 238 patients, KPS
score and body weight were found to be stabilized, and no
signiﬁcant cardiovascular adverse reactions were observed.
We followed 259 patients for an observation period of one
year, and the 1-year survival rate was found to be 81.8%
whereas in the previous studies [6–8], the 1-year survival
rate after the traditional target arterial chemoembolization
was reported as 58–75%. Hence in our study, administra-
tion of verapamil by the perfusion approach signiﬁcantly
improved the efﬁcacy of conventional TACE treatment,
enhanced the overall survival of patients and did not lead to
any signiﬁcant adverse reactions of the cardiovascular
system. The common toxicity complications of grade 3–4
that were observed were almost of the same nature and
level as previously reported in the aforementioned studies.
However, 14 patients clinically progressed or suffered
deterioration. We believe that this failure in improvement
in these individuals is attributable, at least in part, to
multiple factors such as higher levels of post-therapy leu-
kopenia and severity of gastrointestinal side effects.
Therefore, further studies will be required to evaluate in
detail the possible inﬂuence of these and other similar
factors in MDR reversal and overall improvement of
hepatocellular carcinoma patients using verapamil as a
chemosensitizer. In conclusion, targeted arterial infusion of
verapamil via perfusion strategy can reverse the MDR in
tumor cells in primary hepatocellular carcinoma patients
and increase the effectiveness of chemotherapy.
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